Blue Owl sits in the middle of the $2T private credit surge
May 31, 2026 Private Credit Is Going Public Blue Owl is a loud signal inside a quiet corner of finance…
Biotech’s Breakout Moment: The Post-GLP-1 Pipeline Is Attracting Serious Capital
Beyond the weight-loss supercycle, a new class of targeted therapies is driving institutional rotation into mid-cap biotech – and the valuation entry points remain compelling.
The Quantum Computing Race Has a New Frontrunner
Why IonQ Is Emerging as the Stock to Watch in the Next Phase of Computational Power
AI needs buildings, not just chips
May 30, 2026 AI needs buildings, not just chips Why Comfort Systems (FIX) keeps getting pulled along by data center…
Eli Lilly (LLY): The GLP-1 Trade Is Bigger Than the Market Thinks
Mounjaro up 125%. Zepbound up 79%. A new oral pill just launched. The growth story keeps widening.
MercadoLibre: The Latin American Super-App Nobody Fully Prices In
49% revenue growth. 84 million active buyers. A fintech arm expanding at 87%. The opportunity is hiding in plain sight.
SpaceX + Tesla: The Merge
May 29, 2026 SpaceX + Tesla: The Merger Nobody Can Quite Price Featured: SpaceX + Tesla: The Merger Nobody Can…
PLTR After the Fastest Quarter in Its Public History: Why the Valuation Debate Has Changed
85% revenue growth. $1.63B in Q1. A Rule of 40 score of 145%. The question now is whether the multiple makes sense — or has already been answered.
Micron Just Crossed $1 Trillion. Here’s What Changed.
A single analyst call rewired how Wall Street thinks about memory chips — and MU hasn’t looked back.
Nvidia Just Printed $81.6 Billion and the Stock Went Down. Here’s What the Tape Is Really Telling You.
NVDA beat hard, guided higher, and still slipped. The market’s reaction might be the most important signal of the quarter.